Onco Wiki / Disease

Classical Hodgkin Lymphoma

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

IDDIS-CHL
TypeDisease
Aliases
Hodgkin disease (NS / MC / LR / LD subtypes)cHLКласична лімфома Ходжкіна
Statusreviewed 2026-04-25 | pending_clinical_signoff
DiseasesNone declared
SourcesSRC-NCCN-BCELL-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology9650/3
icd_10C81.9
who_classificationHodgkin lymphomas — Classical Hodgkin lymphoma per WHO 5th ed. (4 morphologic subtypes — nodular sclerosis, mixed cellularity, lymphocyte-rich, lymphocyte-depleted)

Capabilities

Notes

Stage-driven 1L: early (I-II) → ABVD × 2-4 + ISRT (response-adapted per interim PET-CT Deauville score); advanced (III-IV) → ABVD × 6 OR A+AVD × 6 (ECHELON-1 — brentuximab replaces bleomycin, OS benefit). escBEACOPP for high-risk advanced (more European preference). Differential — mediastinal/hilar adenopathy: sarcoidosis (D86.0–D86.2) mimics cHL on CT and PET/CT (bilateral hilar uptake, mediastinal and subcarinal nodes). Discriminators: histology (Reed-Sternberg CD15+/CD30+ absent in sarcoid; non-caseating granuloma present), serum ACE, calcium, ophthalmology exam. Biopsy mandatory before chemotherapy; steroids before biopsy mask sarcoid granulomata and confound cHL histopathology.

Used By

Actionability

Algorithms

Disease

Indication

Questionnaires

Red flag

Sources